Page 2 - Asia Outside News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Asia outside. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Asia Outside Today - Breaking & Trending Today

New Drug Approval for in-House Developed Anti-Insomnia Drug Dayvigo (Lemborexant) in Hong Kong


New Drug Approval for in-House Developed Anti-Insomnia Drug Dayvigo (Lemborexant) in Hong Kong
First Drug Approval for Dayvigo in Asia Outside of Japan
TOKYO, Mar 2, 2021 - (JCN Newswire) - Eisai Co., Ltd. announced that its Hong Kong subsidiary Eisai (Hong Kong) Co., Ltd. has obtained approval for the in-house-discovered and developed orexin receptor antagonist DAYVIGO (generic name: lemborexant) for the treatment of adults with insomnia, characterized by difficulties with sleep onset and/or sleep maintenance. This approval is the first approval for DAYVIGO in Asia outside of Japan.
DAYVIGO is a dual orexin receptor antagonist that inhibits orexin neurotransmission regulating sleep-wake rhythm by binding competitively to the two subtypes of orexin receptors (OX1R and OX2R). DAYVIGO acts on the orexin neurotransmitter system and is believed to facilitate sleep onset, sleep maintenance, and wake by regulating sleep-wake rhythm. DAYVIGO binds to orexin receptors OX1R and ....

United States , Hong Kong , Kostenloser Wertpapierhandel , Asia Hong Kong , Eisai Hong Kong Co Ltd , Eisai Co Ltd , Institute Of Medicine , National Institute Of Public Health , Public Relations Department , National Academies , International Statistical Classification Of Diseases , Health Problems , America Insomnia , Drug Approval , Asia Outside , Generic Name , Irregular Sleep Wake Rhythm Disorder , Sleep Wake Disorders , Anti Insomnia Drug Market , Clin Sleep , National Institute , International Statistical Classification , Related Health Problems , Research Diagnostic , International Classification , Sleep Disorders ,